Christina Coughlin
CEO at AVACTA GROUP PLC
Replay available
AVACTA GROUP PLC (AVCT) — Phase 1b Faridoxorubicin (AVA6000) Salivary Gland Cancer Data Release
Phase 1b Faridoxorubicin (AVA6000) Salivary Gland Cancer Data Release hosted by AVACTA GROUP PLC (LSE: AVCT) on Investor Meet Company, held 2025-12-17.
Hosted by
Featured presenters
David Liebowitz
Chief Medical Officer at AVACTA GROUP PLC
Ruairidh Edwards
Translational Scientist at AVACTA GROUP PLC
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Avacta Group Plc.
Replay transcript excerpt
WEBVTT NOTE Transcription provided by Deepgram Request Id: 01a043e9-c40a-78f3-9f34-4b007eceb5e7 Created: 2026-08-27T15:50:41.951Z Duration: 2549.367 Channels: 1 00:00:02.879 -- 00:00:04.480 Good morning and welcome to the AVACTA GROUP 00:00:04.480 -- 00:00:07.839 PLC Investor Presentation. Throughout this recorded meeting, investors 00:00:07.839 -- 00:00:09.840 will be in listen only mode. Questions can 00:00:09.840 -- 00:00:11.280 be submitted by the Q and A tab 00:00:11.280 -- 00:00:12.639 situated in the right hand corner of your 00:00:12.639 -- 00:00:14.559 screen. Just simply type in your question and 00:00:14.559 -- 00:00:16.265 press send. The company will not be in 00:00:16.265 -- 00:00:17.785 a position to answer every question received during 00:00:17.785 -- 00:00:19.545 the meeting itself. Have the company can view 00:00:19.545 -- 00:00:21.705 your questions submitted today and publish responses where 00:00:21.705 -- 00:00:23.865 it's appropriate to do so. Before we begin, 00:00:23.865 -- 00:00:25.465 we'd like to submit the following poll. 00:00:25.785 -- 00:00:26.904 I'd now like to hand you over to 00:00:26.904 -- 00:00:28.825 Christina Cocklin, CEO. Good morning. 00:00:30.660 -- 00:00:31.620 Thanks, Paul. 00:00:32.260 -- 00:00:34.260 Good morning, and thank you everyone for joining 00:00:34.260 -- 00:00:37.300 us for the data release for Feridoxorubicin 00:00:37.300 -- 00:00:40.660 in Phase 1b in patients with salivary gland 00:00:40.660 -- 00:00:41.460 cancers. 00:00:41.700 -- 00:00:44.020 I'm joined today by two team members, 00:00:44.595 -- 00:00:47.235 our Chief Medical Officer, Dave Lebowitz, 00:00:47.235 -- 00:00:50.835 and our translational scientist for this program, 00:00:51.635 -- 00:00:52.755 Rory Edwards. 00:00:52.915 -- 00:00:54.355 Let's ...